Welcome to our dedicated page for Lumos Pharma news (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma stock.
Lumos Pharma, Inc. (formerly NASDAQ: LUMO) has communicated that it is a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, with particular emphasis on Pediatric Growth Hormone Deficiency (PGHD). News about Lumos Pharma has frequently centered on the development of its lead candidate, LUM-201, an oral growth hormone secretagogue, and on key corporate milestones.
Company press releases describe a series of clinical updates from the Phase 2 OraGrowtH210 and OraGrowtH212 trials, where LUM-201 is being evaluated in children with moderate PGHD. These updates have highlighted growth outcomes, biomarker changes in IGF-1 and IGFBP-3, and detailed analyses of pulsatile growth hormone secretion patterns under LUM-201 treatment. Lumos Pharma has also reported presentations of these data at major endocrinology and pediatric endocrine conferences in regions including Europe, Latin America, and the Asia-Pacific.
In addition to clinical data, Lumos Pharma’s news flow has included information about regulatory interactions, such as its End of Phase 2 Meeting with the U.S. Food and Drug Administration regarding a potential placebo-controlled Phase 3 trial of LUM-201 in moderate PGHD. Financial updates, including quarterly results and cash position discussions, have also been part of the company’s public communications during its time as a listed entity.
A significant corporate development reported in the news is the successful completion of a tender offer and merger with Double Point Ventures LLC, after which Lumos Pharma’s common stock ceased trading on NASDAQ and the company began operating as a standalone business of Double Point Ventures. For readers reviewing the LUMO news archive, these items collectively provide historical context on Lumos Pharma’s clinical progress, regulatory discussions, financial reporting, and transition from a public company to a privately held business.
Lumos Pharma (NASDAQ:LUMO) recently appointed Dr. David B. Karpf as Chief Medical Officer, effective August 3, 2021. Dr. Karpf brings over 35 years of clinical endocrinology experience and extensive knowledge in biopharmaceutical development, previously serving as Vice President of Clinical Development at Ascendis Pharma. He has been involved in significant clinical advancements, including LUM-201, Lumos Pharma's oral treatment for Pediatric Growth Hormone Deficiency (PGHD), currently undergoing Phase 2 trials. His expertise is expected to significantly enhance Lumos Pharma's clinical capabilities.
Lumos Pharma (NASDAQ:LUMO) announced the promotion of John McKew, PhD, to President effective August 1, 2021, as part of its succession plan. McKew, who has 30 years of experience in developing therapeutics, previously served as COO and Chief Scientific Officer at Lumos, helping advance the company’s clinical and commercial strategies. He has been instrumental in progressing LUM-201, an oral growth hormone stimulating therapy for pediatric growth hormone deficiency. The company focuses on therapeutics for rare diseases and is currently conducting clinical trials for LUM-201.
Lumos Pharma, Inc. (NASDAQ:LUMO) announced the appointment of Dr. Mark Bach to its Clinical Scientific Advisory Board effective July 15, 2021. Dr. Bach brings over 30 years of clinical research experience, particularly in growth hormone-related disorders. He previously held senior positions at ShouTi Inc. and Ascendis Pharma. The company’s leading candidate, LUM-201, is an innovative oral treatment for Pediatric Growth Hormone Deficiency (PGHD) currently in Phase 2 clinical trials. LUM-201 aims to offer a non-injection alternative to existing therapies, having received Orphan Drug Designation in both the US and EU.
Lumos Pharma, a clinical-stage biopharmaceutical company focused on rare diseases, will announce its Q2 2021 financial results on August 5, 2021, before market open. A conference call is scheduled for 11:00 AM ET to discuss financial results and provide updates on clinical activities. Investors can access the live audio webcast or dial in for participation. Lumos Pharma's lead candidate, LUM-201, is under evaluation for Pediatric Growth Hormone Deficiency and has received Orphan Drug Designation in the US and EU.
Lumos Pharma announced updates on clinical trials for LUM-201, aimed at treating Pediatric Growth Hormone Deficiency (PGHD). The Phase 2 OraGrowtH210 Trial's primary outcome data is now expected in the second half of 2023 due to slower than anticipated enrollment primarily caused by COVID-19 restrictions. The FDA has requested an extension of the trial to 12 months. Additionally, the OraGrowtH212 Trial has been initiated, also extending its treatment period to 12 months. As of June 30, 2021, Lumos holds $107.7 million in cash, sufficient for ongoing operations.
Lumos Pharma has initiated the OraGrowtH212 Trial, a Phase 2 study examining LUM-201 for pediatric growth hormone deficiency (PGHD). This trial aims to document the pharmacokinetics and pharmacodynamics of LUM-201, focusing on its pulsatile release of growth hormone. Conducted at a specialized pediatric hospital in Chile, the trial will assess 24 patients on two dose levels: 1.6 mg/kg/day and 3.2 mg/kg/day over six months. Outcomes include growth hormone pulsatility and safety evaluations. CEO Rick Hawkins expressed optimism about the study supporting future regulatory applications.
AUSTIN, Texas, May 19, 2021 – Lumos Pharma (NASDAQ:LUMO), a biopharmaceutical company focused on rare disease therapeutics, announced participation in the Jefferies Virtual Healthcare Conference on June 3, 2021. The company will conduct a live fireside chat from 3:30 PM to 3:55 PM ET and host one-on-one meetings with investors. The chat can be accessed via the conference link and will be available for replay for 30 days on the company’s website. Lumos Pharma is advancing LUM-201, a growth hormone therapy under Phase 2b trial for Pediatric Growth Hormone Deficiency.
Lumos Pharma, Inc. (NASDAQ:LUMO) announced its participation at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021. The company will present live from 10:45 AM to 11:25 AM ET and will also conduct virtual one-on-one meetings with investors. The presentation can be accessed via the company’s website and will be available for replay for 90 days. Lumos Pharma is focused on therapeutics for rare diseases, with its lead candidate, LUM-201, currently in a Phase 2b trial for Pediatric Growth Hormone Deficiency (PGHD).
Lumos Pharma (NASDAQ:LUMO) reported Q1 2021 results, showing a net loss of $8.6 million, contrasting with a net income of $0.3 million in Q1 2020. Cash and cash equivalents increased to $114.1 million from $98.7 million at the end of 2020, supporting operations through ongoing clinical trials. Updated PK/PD data for LUM-201 demonstrated its potential efficacy in pediatric growth hormone deficiency (PGHD) patients using Predictive Enrichment Markers. The ongoing Phase 2b OraGrowtH210 trial is targeting 40-50 sites, with a mid-2022 data readout anticipated.
Lumos Pharma, Inc. (NASDAQ:LUMO) announced it will report Q1 2021 financial results after market close on May 5, 2021. The company will host a conference call and webcast at 4:30 PM ET to discuss these results and update on clinical activities. The lead therapeutic candidate, LUM-201, is currently in a Phase 2b trial for Pediatric Growth Hormone Deficiency and has Orphan Drug Designation in the US and EU. Investors can access the call via phone or webcast, with a replay available for two weeks.
FAQ
What is the current stock price of Lumos Pharma (LUMO)?
What is the market cap of Lumos Pharma (LUMO)?
